CompletedInterventional · Phase 3NCT04184622 ↗Efficacy and Safety of Tirzepatide Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight- Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-1)
CompletedInterventional · Phase 3NCT04660643 ↗Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo for Maintenance of Weight Loss in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight-Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-4)Louis J AronnePIInterventionDrug: Tirzepatide · Other: PlaceboDatesMar 2021 – Apr 2023· Results postedSponsorEli Lilly and CompanyObesityOverweight
CompletedInterventional · Phase 2NCT05295875 ↗A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled and Parallel Group 48-Week Study to Evaluate the Efficacy and Safety of ALT-801 in the Treatment of Obesity (MOMENTUM Trial)Louis J AronnePIInterventionDrug: ALT-801 · Other: PlaceboDatesMar 2022 – Sep 2023SponsorAltimmune, Inc.Obesity/Overweight
CompletedInterventional · Phase 3NCT05394519 ↗Efficacy and Safety of Cagrilintide s.c. 2.4 mg in Combination With Semaglutide s.c. 2.4 mg (CagriSema s.c. 2.4 mg/2.4 mg) Once-weekly in Participants With Overweight or Obesity and Type 2 DiabetesAlpana P. ShuklaPIInterventionDrug: Cagrilintide · Drug: Semaglutide · Drug: Placebo cagrilintide · Drug: Placebo semaglutideDatesFeb 2023 – Jan 2025SponsorNovo Nordisk Pharmaceuticals, Inc.OverweightObesityType 2 Diabetes Mellitus
CompletedInterventional · Phase 2NCT05616013 ↗A Randomized, Double-Blind, Placebo-Controlled Multi-Center Study of Intravenous Bimagrumab, Alone or in Addition to Open Label Subcutaneous Semaglutide, to Investigate the Efficacy and Safety in Overweight or Obese Men and WomenLouis J AronnePIInterventionBiological: Bimagrumab · Drug: Semaglutide · Other: PlaceboDatesNov 2022 – May 2024· Results postedSponsorVersanis BioObesityObeseOverweight or Obesity
CompletedInterventional · Phase 3NCT05822830 ↗A Phase 3b, Randomized Controlled Study to Evaluate the Efficacy and Safety of Tirzepatide Compared to Semaglutide in Adults Who Have Obesity or Overweight With Weight Related ComorbiditiesAlpana P. ShuklaPIInterventionDrug: Tirzepatide · Drug: SemaglutideDatesApr 2023 – Nov 2024· Results postedSponsorEli Lilly and CompanyObesityOverweight
CompletedInterventional · Phase 3NCT06584916 ↗A Phase 3b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Orforglipron Once Daily Versus Placebo for Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related ComorbiditiesAlpana P. ShuklaPIInterventionDrug: Orforglipron · Drug: PlaceboDatesSep 2024 – Nov 2025SponsorEli Lilly and CompanyObesityOverweight